IQ-AI Limited (IQAI)

Sector:

Health Care

1.34p
   
  • Change Today:
      0.043p
  • 52 Week High: 5.70
  • 52 Week Low: 1.05
  • Currency: UK Pounds
  • Shares Issued: 221.71m
  • Volume: 6,993
  • Market Cap: £2.98m

IQ-AI subsidiary sees tech installed at important tumour centre

By Josh White

Date: Tuesday 11 Dec 2018

LONDON (ShareCast) - (Sharecast News) - IQ-AI subsidiary Imaging Biometrics (IB) announced on Tuesday that Barrow Neurological Institute: Dignity Health, St. Joseph's Hospital and Medical Center (BNI) has installed a new 'IB Rad Tech' software platform, to help assess treatment response for patients with brain tumours.
The London-listed company said BNI had "led the way" in the development of top diagnosis, treatment, and neurosurgical procedures for patients with brain tumours.

It said that each year, Barrow treated thousands of patients with brain tumours, including some of the most difficult cases in the world.

IB Rad Tech was reportedly chosen for its ability to efficiently generate quantitative maps of enhancing regions of tumour, and fractional tumour burden.

IB's perfusion-derived fractional tumour burden maps had been shown to aid clinicians in distinguishing tumour from non-tumour tissue.

The company said IB Rad Tech offered custom workflows that automated the generation of sophisticated maps, output quality assurance indices, and could allow manual acknowledgement and intervention during intermediate processing steps.

For example, one workflow used in generating quantitative Delta T1 and fractional tumour burden maps relied on an exclusive machine-learned calibration technology termed 'standardisation', which worked for all platforms and field strengths.

That step had proven superior to conventional normalisation techniques, IB said, as it eliminated the need for the manual placement of regions of interest by radiology staff or physicians, thus reducing error and improving workflow efficiencies.

"Using this automated normalisation algorithm within an IB Rad Tech workflow enables objective longitudinal assessment and can help assess whether a certain treatment protocol is working for brain tumour patients," siad Imaging Biometrics chief executive officer David Smith.

"Removing the variability of the manually-placed regions of interest is a more repeatable and faster method to do inter- and intra-study comparisons for multi-centre clinical trials as well."

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

IQ-AI Limited Market Data

Currency UK Pounds
Share Price 1.34p
Change Today 0.043p
% Change 3.30 %
52 Week High 5.70
52 Week Low 1.05
Volume 6,993
Shares Issued 221.71m
Market Cap £2.98m

IQ-AI Limited Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
75.67% below the market average75.67% below the market average75.67% below the market average75.67% below the market average75.67% below the market average
61.29% below the sector average61.29% below the sector average61.29% below the sector average61.29% below the sector average61.29% below the sector average
Price Trend
85.57% below the market average85.57% below the market average85.57% below the market average85.57% below the market average85.57% below the market average
45.95% below the sector average45.95% below the sector average45.95% below the sector average45.95% below the sector average45.95% below the sector average
Income Not Available
Growth
15.33% above the market average15.33% above the market average15.33% above the market average15.33% above the market average15.33% above the market average
9.09% above the sector average9.09% above the sector average9.09% above the sector average9.09% above the sector average9.09% above the sector average

IQ-AI Limited Dividends

No dividends found

Trades for 23-Jul-2024

Time Volume / Share Price
08:04 6,993 @ 1.22p

Top of Page